Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
CSF Biomarkers of Alzheimer’s Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design
Saved in:
| Published in: | Advances in Geriatrics |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2014
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: CSF Biomarkers of Alzheimer’s Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design
- Interchangeability of CSF and PET to identify Alzheimer's disease pathology
- Perceptions of the use of biomarkers for Alzheimer's disease diagnosis: A systematic review and synthesis of the qualitative literature
- Blood DNA methylation signature of cognitive reserve moderates the association between CSF tau pathology and memory in prodromal Alzheimer's disease
- A fovea‐centered retinal signature linked to plasma biomarkers in prodromal Alzheimer's disease
- Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatment
- Physical activity attenuates the association between allostatic load and early Alzheimer's disease‐related biomarkers in older adults